Shilpa Ramla1, Vinay Sharma2, Mrudula Patel3. 1. Division of Oral Microbiology, Department of Oral Biological Sciences, School of Oral Health Sciences, Faculty of Health Sciences, University of The Witwatersrand, 7 York Road, Parktown, Johannesburg, 2050, South Africa. 2. Radiation Oncology, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. Division of Oral Microbiology, Department of Oral Biological Sciences, School of Oral Health Sciences, Faculty of Health Sciences, University of The Witwatersrand, 7 York Road, Parktown, Johannesburg, 2050, South Africa. mrudula.patel@wits.ac.za.
Abstract
PURPOSE: Cancer treatment causes mucositis and the manifestation of oral candidiasis. This study investigated the virulence properties and antifungal susceptibilities of Candida albicans isolated from cancer patients undergoing therapy. METHODS: C. albicans were isolated from 49 patients on cancer treatment and 21 healthy individuals and their virulence attributes measured. A correlation was determined between the length of treatment and the fungal counts and their virulence factors. RESULTS: Although Candida carriage was similar in all the study groups, high quantities of C. albicans and variety of Candida were found in cancer patients. Germ tubes were produced by all the strains. Significantly high number of yeast isolated from radiotherapy and chemotherapy produced large quantities of phospholipase compared to healthy individuals (p < 0.01). The length of chemotherapy was associated with an increase in the phospholipase production (p = 0.03) by the C. albicans. Proteinase production was seen in a significant number of isolates from the radiotherapy group (p < 0.01). Type of cancer treatment had no effect. Resistance to antifungal agents was low. CONCLUSIONS: High quantities of phospholipase were produced by C. albicans in cancer patients on therapy which also increased with the length of chemotherapy suggesting enhanced risk of oral and systemic infection. Therefore, during treatment, prophylactic topical antifungal therapy may be considered.
PURPOSE:Cancer treatment causes mucositis and the manifestation of oral candidiasis. This study investigated the virulence properties and antifungal susceptibilities of Candida albicans isolated from cancerpatients undergoing therapy. METHODS:C. albicans were isolated from 49 patients on cancer treatment and 21 healthy individuals and their virulence attributes measured. A correlation was determined between the length of treatment and the fungal counts and their virulence factors. RESULTS: Although Candida carriage was similar in all the study groups, high quantities of C. albicans and variety of Candida were found in cancerpatients. Germ tubes were produced by all the strains. Significantly high number of yeast isolated from radiotherapy and chemotherapy produced large quantities of phospholipase compared to healthy individuals (p < 0.01). The length of chemotherapy was associated with an increase in the phospholipase production (p = 0.03) by the C. albicans. Proteinase production was seen in a significant number of isolates from the radiotherapy group (p < 0.01). Type of cancer treatment had no effect. Resistance to antifungal agents was low. CONCLUSIONS: High quantities of phospholipase were produced by C. albicans in cancerpatients on therapy which also increased with the length of chemotherapy suggesting enhanced risk of oral and systemic infection. Therefore, during treatment, prophylactic topical antifungal therapy may be considered.
Authors: C Lass-Flörl; M C Arendrup; J-L Rodriguez-Tudela; M Cuenca-Estrella; P Donnelly; W Hope Journal: Clin Microbiol Infect Date: 2011-10-19 Impact factor: 8.067
Authors: A Safdar; V Chaturvedi; E W Cross; S Park; E M Bernard; D Armstrong; D S Perlin Journal: Antimicrob Agents Chemother Date: 2001-07 Impact factor: 5.191
Authors: S W Redding; R C Zellars; W R Kirkpatrick; R K McAtee; M A Caceres; A W Fothergill; J L Lopez-Ribot; C W Bailey; M G Rinaldi; T F Patterson Journal: J Clin Microbiol Date: 1999-12 Impact factor: 5.948
Authors: Eric F Kong; Sona Kucharíková; Patrick Van Dijck; Brian M Peters; Mark E Shirtliff; Mary Ann Jabra-Rizk Journal: Infect Immun Date: 2014-11-24 Impact factor: 3.441
Authors: Yaoping Liu; Amol C Shetty; Jennifer A Schwartz; L Latey Bradford; Wenjie Xu; Qyunh T Phan; Priti Kumari; Anup Mahurkar; Aaron P Mitchell; Jacques Ravel; Claire M Fraser; Scott G Filler; Vincent M Bruno Journal: Genome Res Date: 2015-04-09 Impact factor: 9.043
Authors: T Sobue; M Bertolini; A Thompson; D E Peterson; P I Diaz; A Dongari-Bagtzoglou Journal: Mol Oral Microbiol Date: 2018-02-20 Impact factor: 3.563